An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients

Blandine Dozières-Puyravel,1 Stéphane Auvin1,2 1Service de Neurologie Pédiatrique et des Maladies Métaboliques, Hôpital Robert Debré, Paris, France; 2Université Paris Diderot, Sorbonne Paris Cité, INSERM UMR 1141,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dozières-Puyravel B, Auvin S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Antiepileptic drugs Children Epilepsy Focal Onset Seizure Perampanel Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/884fea2d5bdf4524996e3a362e9869c3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:884fea2d5bdf4524996e3a362e9869c3
record_format	dspace
spelling	oai:doaj.org-article:884fea2d5bdf4524996e3a362e9869c32021-12-02T07:05:35ZAn Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients1178-2021https://doaj.org/article/884fea2d5bdf4524996e3a362e9869c32019-09-01T00:00:00Zhttps://www.dovepress.com/an-evidence-based-review-on-the-use-of-perampanel-for-the-treatment-of-peer-reviewed-article-NDThttps://doaj.org/toc/1178-2021Blandine Dozières-Puyravel,1 Stéphane Auvin1,2 1Service de Neurologie Pédiatrique et des Maladies Métaboliques, Hôpital Robert Debré, Paris, France; 2Université Paris Diderot, Sorbonne Paris Cité, INSERM UMR 1141, Paris, FranceCorrespondence: Stéphane AuvinService de Neurologie Pédiatrique et des Maladies Métaboliques, CHU Hôpital Robert Debrém, 48, Boulevard Sérurier, Paris CEDEX 19- 75935, FranceTel +33 1 40 03 57 24Fax +33 1 40 03 47 74Email stephane.auvin@aphp.frAbstract: Perampanel, a non-competitive AMPA receptor antagonist, is a once-daily oral antiepileptic drug approved for the treatment of focal seizures and primary generalized tonic–clonic seizures in children 12 years of age and over. We conducted a systematic review of the data on perampanel in children and adolescents with focal-onset seizures. We found 21 published papers on the pediatric use of perampanel for focal-onset seizures, including 9 papers on clinical trials and ancillary studies of these trials, of which 2 focused on pharmacokinetics, 1 was a meta-analysis, and 9 were real-life studies (1 was prospective). Perampanel, as an adjunctive treatment for uncontrolled focal-onset seizures, results in an improvement of seizure control with a generally good safety profile. Evidence-based data are currently available for children 12 years of age and over. Higher amounts of perampanel might be required in patients taking enzyme-inducing antiepileptic drugs. The most common adverse events are somnolence, dizziness and behavioral adverse events. The latter seems more frequent in adolescents than in adults and in adolescents with preexisting behavioral comorbidities. Current studies did not identify any short-term impact of perampanel on cognitive functions. Its long half-life allows once-daily administration. Real-life studies further established that a decrease of the dose frequently resolves adverse events, as demonstrated in pivotal studies. Pharmacokinetic and safety studies are still ongoing in the younger population, down to 4 years of age, in order to apply for approval in this age group.Keywords: antiepileptic drugs, children, epilepsy, focal onset seizure, perampanelDozières-Puyravel BAuvin SDove Medical PressarticleAntiepileptic drugsChildrenEpilepsyFocal Onset SeizurePerampanelNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 15, Pp 2789-2798 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Antiepileptic drugs Children Epilepsy Focal Onset Seizure Perampanel Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Antiepileptic drugs Children Epilepsy Focal Onset Seizure Perampanel Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Dozières-Puyravel B Auvin S An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients
description	Blandine Dozières-Puyravel,1 Stéphane Auvin1,2 1Service de Neurologie Pédiatrique et des Maladies Métaboliques, Hôpital Robert Debré, Paris, France; 2Université Paris Diderot, Sorbonne Paris Cité, INSERM UMR 1141, Paris, FranceCorrespondence: Stéphane AuvinService de Neurologie Pédiatrique et des Maladies Métaboliques, CHU Hôpital Robert Debrém, 48, Boulevard Sérurier, Paris CEDEX 19- 75935, FranceTel +33 1 40 03 57 24Fax +33 1 40 03 47 74Email stephane.auvin@aphp.frAbstract: Perampanel, a non-competitive AMPA receptor antagonist, is a once-daily oral antiepileptic drug approved for the treatment of focal seizures and primary generalized tonic–clonic seizures in children 12 years of age and over. We conducted a systematic review of the data on perampanel in children and adolescents with focal-onset seizures. We found 21 published papers on the pediatric use of perampanel for focal-onset seizures, including 9 papers on clinical trials and ancillary studies of these trials, of which 2 focused on pharmacokinetics, 1 was a meta-analysis, and 9 were real-life studies (1 was prospective). Perampanel, as an adjunctive treatment for uncontrolled focal-onset seizures, results in an improvement of seizure control with a generally good safety profile. Evidence-based data are currently available for children 12 years of age and over. Higher amounts of perampanel might be required in patients taking enzyme-inducing antiepileptic drugs. The most common adverse events are somnolence, dizziness and behavioral adverse events. The latter seems more frequent in adolescents than in adults and in adolescents with preexisting behavioral comorbidities. Current studies did not identify any short-term impact of perampanel on cognitive functions. Its long half-life allows once-daily administration. Real-life studies further established that a decrease of the dose frequently resolves adverse events, as demonstrated in pivotal studies. Pharmacokinetic and safety studies are still ongoing in the younger population, down to 4 years of age, in order to apply for approval in this age group.Keywords: antiepileptic drugs, children, epilepsy, focal onset seizure, perampanel
format	article
author	Dozières-Puyravel B Auvin S
author_facet	Dozières-Puyravel B Auvin S
author_sort	Dozières-Puyravel B
title	An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients
title_short	An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients
title_full	An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients
title_fullStr	An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients
title_full_unstemmed	An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients
title_sort	evidence-based review on the use of perampanel for the treatment of focal-onset seizures in pediatric patients
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/884fea2d5bdf4524996e3a362e9869c3
work_keys_str_mv	AT dozierespuyravelb anevidencebasedreviewontheuseofperampanelforthetreatmentoffocalonsetseizuresinpediatricpatients AT auvins anevidencebasedreviewontheuseofperampanelforthetreatmentoffocalonsetseizuresinpediatricpatients AT dozierespuyravelb evidencebasedreviewontheuseofperampanelforthetreatmentoffocalonsetseizuresinpediatricpatients AT auvins evidencebasedreviewontheuseofperampanelforthetreatmentoffocalonsetseizuresinpediatricpatients
_version_	1718399646093541376

An Evidence-Based Review On The Use Of Perampanel For The Treatment Of Focal-Onset Seizures In Pediatric Patients

Ejemplares similares